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Abstract
Background: Traumatic injury to axons produces breakdown of axons and myelin at the site of the lesion and
then further distal to this where Wallerian degeneration develops. The rapid removal of degenerated myelin by
phagocytosis is advantageous for repair since molecules in myelin impede regeneration of severed axons. Thus,
revealing mechanisms that regulate myelin phagocytosis by macrophages and microglia is important. We
hypothesize that myelin regulates its own phagocytosis by simultaneous activation and down-regulation of
microglial and macrophage responses. Activation follows myelin binding to receptors that mediate its phagocytosis
(e.g. complement receptor-3), which has been previously studied. Down-regulation, which we test here, follows
binding of myelin CD47 to the immune inhibitory receptor SIRPa (signal regulatory protein-a) on macrophages
and microglia.
Methods: CD47 and SIRPa expression was studied by confocal immunofluorescence microscopy, and myelin
phagocytosis by ELISA.
Results: We first document that myelin, oligodendrocytes and Schwann cells express CD47 without SIRPa and
further confirm that microglia and macrophages express both CD47 and SIRPa. Thus, CD47 on myelin can bind to
and subsequently activate SIRPa on phagocytes, a prerequisite for CD47/SIRPa-dependent down-regulation of
CD47
+/+ myelin phagocytosis by itself. We then demonstrate that phagocytosis of CD47
+/+ myelin is augmented
when binding between myelin CD47 and SIRPa on phagocytes is blocked by mAbs against CD47 and SIRPa,
indicating that down-regulation of phagocytosis indeed depends on CD47-SIRPa binding. Further, phagocytosis in
serum-free medium of CD47
+/+ myelin is augmented after knocking down SIRPa levels (SIRPa-KD) in phagocytes
by lentiviral infection with SIRPa-shRNA, whereas phagocytosis of myelin that lacks CD47 (CD47
-/-) is not. Thus,
myelin CD47 produces SIRPa-dependent down-regulation of CD47
+/+ myelin phagocytosis in phagocytes.
Unexpectedly, phagocytosis of CD47
-/- myelin by SIRPa-KD phagocytes, which is not altered from normal when
tested in serum-free medium, is augmented when serum is present. Therefore, both myelin CD47 and serum may
each promote SIRPa-dependent down-regulation of myelin phagocytosis irrespective of the other.
Conclusions: Myelin down-regulates its own phagocytosis through CD47-SIRPa interactions. It may further be
argued that CD47 functions normally as a marker of “self” that helps protect intact myelin and myelin-forming
oligodendrocytes and Schwann cells from activated microglia and macrophages. However, the very same
mechanism that impedes phagocytosis may turn disadvantageous when rapid clearance of degenerated myelin is
helpful.
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Oligodendrocytes in the central nervous system (CNS) and
Schwann cells in the peripheral nervous system (PNS)
form specialized myelin extensions of their plasma mem-
branes that surround axons normally enabling them rapid
conduction of electrical activity. Traumatic injury to axons
produces abrupt breakdown of axons and myelin where
physical trauma occurs. Then, axons and myelin also
break down distal to the lesion as Wallerian degeneration
(WD) develops [1]. Degenerated myelin is phagocytosed at
injury sites in traumatized CNS by activated resident
microglia and by activated blood-borne macrophages that
gain access to the site through ruptured vasculature. In
contrast, macrophages are not recruited and resident
microglia are not activated to phagocytose degenerated
myelin distal to lesion where CNS-WD develops [2-4].
Consequently, myelin-associated inhibitory molecules (e.g.
Nogo, OMgp and MAG) impede axonal regeneration and
repair; reviewed most recently in [5,6]. Blood-borne
macrophages that are scarce in intact PNS are recruited
and activated along with resident Schwann cells to remove
degenerated myelin by phagocytosis during PNS-WD and
regeneration of severed PNS axons follows [2,7,8]. How-
ever, PNS repair is often not successful in humans as it is
in mice and rats [9,10]. This discrepancy has been attribu-
ted, in part, to the several-fold longer nerve segments that
need to be cleared of degenerated myelin in humans. This
results in delayed onset and slower axonal regeneration
which contrasts with the prompt regeneration and rein-
nervation that are the most important determinants of
good functional recovery. Therefore, revealing mechan-
isms that slow down myelin clearance is important.
We presently test the hypothesis that myelin regulates
its own phagocytosis by simultaneous activation and
down-regulation of microglia/macrophages (Figure 1A &
1B). Activation follows myelin binding and subsequently
activation of receptors that mediate its phagocytosis; CR3
(complement receptor-3), SRA (scavenger receptor-AI/II)
and FcgR (Fcg receptor) [11-15]. CR3 and SRA contribute
most to phagocytosis in the absence of anti-myelin Abs, as
is the case following axonal injury in-vivo and in our assay
system. Further, of the two, CR3 contributes two- to
three-fold more to phagocytosis than SRA. FcgR mediates
myelin phagocytosis when anti-myelin Abs are present
and opsonize myelin, as in multiple sclerosis. Down-
regulation may follow myelin binding and subsequent
activation of immune inhibitory receptors, which has not
been previously studied. We specifically test here whether
phagocytosis by macrophages and microglia is down-
regulated after myelin-associated CD47 binds to the
immune inhibitory receptor SIRPa on phagocytes.
SIRPa (CD172a, SHPS-1, p84, gp93, and BIT) is a
member of an immune inhibitory family of receptors
that down-regulate innate immune functions in myeloid
cells; reviewed recently in [16-18]. SIRPa is expressed
also on neurons. CD47, known also as IAP (integrin
associated protein), is a SIRPa ligand and itself an
SIRPa and thrombospondin receptor. CD47 is expressed
on myeloid cells, RBCs (red blood cells), platelets,
neurons, fibroblasts and endothelial cells [19,20]. CD47
expression on myelin and myelin-forming oligodendro-
cytes and Schwann cells has not been previously
reported.
CD47-SIRPa binding requires cell-cell contact since
both are cell membrane protein receptors. Previous
reports have documented that RBCs and platelets that
were opsonized by Ab/IgG or complement protein C3bi
down-regulate their own phagocytosis by FcgRa n dC R 3
in macrophages after CD47 on RBCs and platelets binds
SIRPa on phagocytes. These observations led to the
classification of CD47 as a marker of “self” whose func-
tion is to protect intact cells from being phagocytosed
by autologous macrophages [21-24].
We presently demonstrate that wild-type myelin that
expresses CD47 (CD47
+/+) down-regulates its own pha-
gocytosis by microglia and macrophages after myelin
CD47 binds SIRPa on phagocytes. CD47 may function,
therefore, as a marker of “self” in myelin and myelin-
forming oligodendrocytes and Schwann cells. We
further document that components in serum may also
promote SIRPa-dependent down-regulation of myelin
phagocytosis irrespective of myelin CD47.
Methods
Animals Sprauge-Dawley rats and wild-type and
CD47
-/- Balb/C mice that were obtained from Harlan
(Israel) and [21] were handled in accordance with the
national research council’s guide for the care and use of
laboratory animals and the approval of the institutional
committee.
Thioglycollate-elicited peritoneal primary macro-
phages w e r eh a r v e s t e di nc o l dD M E M / F 1 23t o4d a y s
after intraperitoneal injection of 75μL/gram body weight
of 3% thioglycollate (Difco, USA), and plated in the pre-
sence of 10% heat-inactivated FCS in 96-well culture
plates (Nunc International, USA) for 2 hours. Non-
adherent cells were washed away. The remaining
adhered cells are macrophages that express Galectin-3
(formally known as MAC-2) (Figure 2A), CR3 and F4/
80 [8,25,26].
Primary microglia were isolated from brains of neo-
natal mice and rats as previously described [11]. In
brief, the brains were stripped of their meninges and
enzymatically dissociated, and cells were then plated on
poly-L-lysine coated flasks for one week and replated for
1 to 2 hours on bacteriological plates. Non-adherent
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adherent cells are microglia judged by morphology and
positive immunoreactivity to Galectin-3/MAC-2 (Figure
2E), CR3 and F4/80 [4,27].
Mixed cell cultures; Schwann cells and fibroblasts
from PNS and astrocytes and oligodendrocytes from
CNS were obtained as previously described [4,8,28]. In
brief, neonate brains (i.e. CNS) and sciatic nerves (i.e.
PNS) were cut into small pieces. The brains were incu-
bated for 1 hour in DMEM containing 0.25% trypsin.
The nerves were incubated for 18 to 20 hours in DMEM
containing 1.2 units/ml dispase (Boehringer), 0.05% col-
lagenase and 0.1% hyaluronidase (Sigma, Israel). Disso-
ciated tissues were plated on laminin-coated culture
dishes or bacteriological plates. Cells were identified by
their source, morphology and immunoreactivity to speci-
fic markers. In PNS cultures [8,28], Schwann cells
displayed bipolar, spindle-shaped morphology, were
S-100- and Galectin-3/MAC-2-positive but F4/80- and
CR3-negative. Fibroblasts were flat, F4/80-, CR3-, S-100-
and Galectin-3/MAC-2-negative cells. In CNS cultures
[4], astrocytes were GFAP-positive but F4/80-, CR3-,
Galectin-3/MAC-2- and Gal-C-negative. Oligodendro-
cytes displayed a characteristic arbor of thin, elongated,
branched processes and were Gal-C-positive but GFAP-,
F4/80-, CR3- and Galectin-3/MAC-2-negative.
Myelin phagocytosis
Microglia and macrophages were plated in 96-well tissue
culture plates at a density that minimizes cell-cell contact
(0.25-1.5 × 10
4/well) in the presence of DMEM supple-
mented by 10% HI-FCS (heat inactivated FCS).
Non-adherent cells were washed out after 2 hours and
adherent phagocytes left to rest overnight. Then phago-
cytes were washed, myelin added for 60 minutes in the
presence of serum in DMEM/F12, unphagocytosed mye-
lin washed out, and levels of phagocytosis determined by
ELISA (see below). At this point remaining myelin has
already been phagocytosed/internalized (Figure 2D; see
also [29]). When testing phagocytosis in the presence of
anti-SIRPa m A b( 2t o5μg/ml), phagocytes were pre-
incubated in the presence of mAb or matched control
IgG in triplicates for 30 minutes and phagocytosis
assayed in their continuous presence at 37°C (Figure 1C).
When testing phagocytosis of myelin whose CD47 was
blocked by anti-CD47 mAb, myelin was first pre-
incubated with anti-CD47 (5 μg/ml) or matched control
IgG in a ratio of 1:1 for 30 minutes at 37°C and unbound
mAb washed away. However, before blocking CD47 on
myelin, Fc-segments of anti-CD47 and control IgG were
blocked/coated by incubating them with Fab2 fragments
of goat anti-mouse IgG in a ratio of 1:5 for 30 minutes at
37°C. Myelin opsonized by Fc-coated anti-CD47 or Fc-
coated control IgG was added to phagocytes and phago-
cytosis assayed (Figure 1D). When testing phagocytosis
in the absence of serum, phagocytes were washed and
incubated in serum-free media supplemented by 0.1%
delipidated BSA (MP Biomedicals, Inc) for 4 hours,
washed, and phagocytosis was then assayed in serum-free
DMEM/F12 supplemented by 0.1% delipidated BSA.
ELISA assay to quantify myelin phagocytosis
This assay is based on the detection of myelin basic
protein (MBP) in macrophages and microglia lysates.
Figure 1 Myelin regulates its own phagocytosis by simultaneous activation and down-regulation - a schematic representation of the
working hypothesis and experimental design. (A & B) Degenerated wild-type CD47
+/+ (CD47) myelin can simultaneously bind CR3 and
SIRPa, which are expressed on microglia and macrophages. (A) Myelin binds CR3, which is the major receptor that mediates myelin
phagocytosis in context of traumatic injury (see text), either directly or indirectly after being opsonized by complement protein C3bi (± C3bi).
CR3 ligation initiates a signaling cascade that activates phagocytosis. (B) SIRPa ligation by myelin CD47 initiates a signaling cascade that inhibits
phagocytosis by down-regulating signaling produced by CR3. (C & D) Augmentation of phagocytosis is anticipated if CD47 binding to SIRPa is
blocked by either anti-SIRPa or anti-CD47 mAbs. (C) SIRPa on phagocytes is blocked by anti-SIRPa mAbs. (D) Myelin CD47 is blocked by anti-
CD47 mAbs whose Fc-segments (black circle) are coated with anti-Fc-Fab2 fragments that lack their own Fc-segments. (E) Myelin CD47 is
blocked by anti-CD47 mAbs whose Fc-segments are exposed. Consequently, CD47 binding to SIRPa is blocked (as in D) but binding to and
activation of phagocytosis through FcgR is possible. (F) However, if anti-CD47 Fc-segments are coated by anti-Fc-Fab2 fragments (as in D),
binding to and activation of phagocytosis through FcgR are blocked. Phagocytosis of (H) CD47
+/+ is expected to be augmented after reduction
of SIRPa levels in phagocytes; i.e. compared to phagocytosis of CD47
+/+ by (G) phagocytes expressing normal SIRPa levels. Further, phagocytosis
of CD47
-/- myelin by phagocytes expressing (I) normal or (J) reduced SIRPa levels are expected to be about the same.
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produced by phagocytes, MBP levels detected in phago-
cyte cytoplasm are proportional to levels of myelin pha-
gocytosed. In brief, after non-phagocytosed myelin was
washed away and remaining myelin had already been
phagocytosed (Figure 2D), phagocytes were lysed
(0.05 M carbonate buffer, pH 10), the lysates transferred
to high protein absorbance plates (Nalge Nunc Interna-
tional, USA), and levels of MBP were determined by
ELISA using anti-MBP mAbs. A detailed protocol is
Figure 2 Macrophages and microglia express CD47 and SIRPa whereas myelin, Schwann cells, oligodendrocytes and astrocytes
express CD47 without SIRPa. Macrophages (MO) express (A) Galectin-3, cell surface (B) SIRPa, and (C) CD47. (D) Macrophages phagocytose
myelin. F-actin (filamentous actin) is visualized by Alexa 488 labeled phalloidin (green) and myelin by anti-MBP mAb (red); overlap between the
two is yellow. Myelin is present in the cytoplasm interior to cortical F-actin. Similar observations were made in microglia (not shown; see [29]).
Microglia (MG) express (E) Galectin-3, and cell surface (F) SIRPa and (G) CD47. (H) MBP and (J) CD47 are expressed in myelin without (I) SIRPa. (K)
Anti-Fc-Fab2 fragments coat/block Fc-segments of anti-CD47 mAb that binds CD47 on myelin, thus preventing visualization of anti-CD47 mAb
by a secondary Ab. (L) CD47 is expressed on spindle shaped bipolar Schwann cells (arrow) and flat fibroblasts (double arrow). (M) CD47 is
expressed on oligodendrocytes (arrow) that extend elongated branched processes, and on flat astrocytes (double arrow). Galectin-3, CD47, SIRPa
and MBP are visualized by immunofluorescence confocal microscopy using respective mAbs directed against each (red). Bars are 5 μmi nA
through K, and 50 μm in L and M.
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than 95% of the detected MBP arises from phagocytosed
myelin (see also Figure 2D). We further verified the
validity of this phagocytosis assay by testing the ability
to inhibit myelin phagocytosis down to 5% of control by
cytochalasin-D (not shown).
Quantification of phagocytosis was carried out in the
following way. When phagocytosis by microglia infected
with SIRPa-shRNA (SIRPa-knocked-down; SIRPa-KD
microglia) was compared to phagocytosis by control
microglia infected with non-target Luciferase-shRNA
(Con-Luc microglia), phagocytosis by each was first nor-
malized to the number of respective microglia counted in
1-mm
2 areas at the center of wells. Normalizing phagocy-
tosis to cell number is required since the number of
adherent microglia could differ because SIRPa-KD and
Con-Luc microglia may differ in adhesion properties to
plates. To this end, microglia in replicate plates were
fixed (i.e. instead of being lysed for the phagocytosis
assay), stained and counted. Then, phagocytosis, normal-
ized to cell number by SIRPa-KD microglia, was calcu-
lated as a percentage of phagocytosis normalized to cell
number by Con-Luc microglia, which was defined as
100%. When phagocytosis by wild-type microglia was
tested in the presence of anti-SIRPa, anti-CD47 or con-
trol IgG (see above), phagocytosis in the presence of
either anti-SIRPa or anti-CD47 was calculated as percen-
tage of phagocytosis in control IgG, which was defined as
100%. In this case, phagocytosis was not normalized to
cell number since we confirmed that the number of
adherent cells did not differ between wells, as the same
population of wild-type microglia was tested in all wells.
Myelin isolation from mouse and rat brains has been
previously described [13,26].
Media products
DMEM, DMEM/F12, FCS, Gentamycin sulfate, and
L-Glutamine were obtained from Biological Industries
(Beit-Haemek, Israel).
Immunocytochemistry
Cells or myelin were plated, fixed for 20 min at RT in
4% Formaldehyde in PBS, washed, blocked over night at
4°C in 10% FCS in PBS, incubated for 1.5 hours at 37°C
in either anti-CD47 (5 μg/ml), anti-SIRPa (5 μg/ml), or
anti-MBP (2 μg/ml), washed, incubated in Cy3 labeled
rabbit anti-mouse Abs for 40 minutes at RT, washed
and mounted. For combined myelin and F-actin stain-
ing, fixed cells were permeabilized for 10 minutes at RT
in 0.01% Triton × -100 (Sigma Aldrich, Israel) in
PBS, washed, blocked for 2 hours at 37°C in 10% FCS
in PBS, incubated for 1.5 hours at 37°C in anti-MBP
(2 μg/ml), washed, incubated in Cy3 labeled donkey anti-rat
Abs and alexa fluor 488 phalloidin (1:100) for 40 minutes,
washed and mounted. For Galectin-3 staining, permeabi-
lized and blocked cells were incubated for 1.5 hours at
37°C in mouse anti-rat Galectin-3 (4 μg/ml), washed and
incubated for 40 minutes at RT in Cy3-labeled rabbit
anti-mouse, washed and mounted.
Generation of microglia with stable reduced SIRPa
expression
Reduction of SIRPa expression was achieved through len-
tiviral infection of wild-type Balb/C microglia with short
hairpin RNAs directed against mouse SIRPa mRNA
(SIRPa-shRNA) using pLKO.1 puro plasmids (Sigma,
Israel). Four different shRNA sequences were used. All
were effective in reducing SIRPa expression and the one
selected for this study is in the SIRPa cDNA coding
sequence 5’CCGGTGGTTCAAAGAACTCGAGTTCTTG
CCCATCTTTGAACCATTTTTG-3’.T h ep l a s m i dw a s
transfected into a 293T-based packaging cell line, and the
resulting culture supernatant was used for lentiviral infec-
tion. Infected microglia were selected on the basis of their
resistance to puromycin brought by the pLKO.1 plasmid.
The level of SIRPa protein expression was monitored by
western blotting. As a control, microglia were infected in a
similar way with the shRNA sequence 5’CTTACGCT-
GAGTACTTCGA-3’ against the non-target firefly Lucifer-
ase gene (a gift from Dr I. Ben-Porath).
Antibody source
Mouse anti-rat CD47 and SIRPa/CD172a mAbs, rat
anti-mouse MBP mAb and matched control IgG - Sero-
tec (Oxford, England), anti-rat Galectin-3 mAb - Santa
Cruz (USA), rat anti-mouse Galectin-3 mAb (M3/38
hybridoma cell line; American Type Culture Collection,
Rockville, MD, USA), Cy3-labeled rabbit anti-mouse,
Fab2 fragment goat anti-mouse IgG, and anti-normal rat
IgG - Jackson (West Grove, USA).
Confocal fluorescence microscopy was carried out
using an Olympus FluoView FV1000 confocal micro-
scope. Alexa Fluor 488-labeled phalloidin (Molecular
Probes, USA) was used to visualize F-actin. Optical
slices of phagocytes, 1 μm thick, were scanned
sequentially.
Statistical analysis
Non-parametric Mann-Whitney analysis was carried out
and all p-values of significance are two tailed. Values of
individual experiments as well as averages ± SE are given.
Results
CD47 and SIRPa are expressed on macrophages and
microglia, and CD47 without SIRPa on myelin, Schwann
cells and oligodendrocytes
A pre-requisite for wild-type myelin inhibiting its
own phagocytosis through CD47-SIRPa interactions
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and SIRPa on macrophages and microglia. We exam-
ined, therefore, whether CD47 and/or SIRPa are
expressed on myelin and myelin-forming Schwann cells
and oligodendrocytes, which has not been previously
reported. We further sought to confirm that phagocytes
used in this study express CD47 and SIRPa. Rat and
mouse microglia, astrocytes, oligodendrocytes and mye-
lin were isolated from brains, Schwann cells and fibro-
blasts from sciatic nerves, and thioglycollate-elicited
macrophages from the peritoneal cavity. The identity of
each cell type was verified by its source, morphology
and specific markers (see Methods). Amongst these we
present here are positive immunoreactivity to Galectin-
3/MAC-2 in macrophages and microglia (Figure 2A
&2E) and to MBP in myelin (Figure 2H). Macrophages
and microglia are also immunoreactive to both SIRPa
and CD47 (Figure 2B, C, F &2G). Myelin, Schwann
cells, oligodendrocytes, astrocytes and fibroblasts are
immunoreactive to CD47 but not SIRPa (Figure 2I, J, L
&2M). Negative immunoreactivity to SIRPa in Schwann
cells, oligodendrocytes, fibroblasts and astrocytes is not
shown. Similar patterns of Galectin-3/MAC-2, CD47
and SIRPa expression were detected in mouse and rat
cells. We chose to present data from rat macrophages,
microglia and myelin (Figure 2A through 2K) since
t h o s ew e r eu s e di nt h ef o r t h c o m i n ge x p e r i m e n ti n
which we test how blocking binding between CD47 and
SIRPa influences phagocytosis.
Myelin phagocytosis is down-regulated after myelin CD47
binds to SIRPa on macrophages and microglia
Down-regulation of myelin phagocytosis, which depends
on binding between CD47 on myelin and SIRPa on
phagocytes, suggests augmentation of phagocytosis
when CD47-SIRPa binding is blocked by mAbs directed
against either one (Figure 1C &1D). We used rat micro-
glia and macrophages to study phagocytosis in the pre-
sence of function-blocking mouse anti-rat CD47 and
SIRPa mAbs since those are commercially available. We
could not use mouse phagocytes in this experiment
since rat anti-mouse CD47 and SIRPa mAbs that are
useful for immunocytochemistry do not block function.
We blocked first SIRPa on rat microglia and macro-
phages by pre-incubating phagocytes with mouse anti-
rat SIRPa mAb or matched control IgG for 30 minutes
(Figure 1C). Myelin was then added and phagocytosis
tested in the continuous presence of anti SIRPa or con-
trol IgG. Phagocytosis by macrophages and microglia
was augmented 280% and 180% of control, respectively
(Figure 3).
We then blocked CD47 on myelin before providing it to
microglia and macrophages. Myelin was pre-incubated in
the presence of mouse anti-rat CD47 mAb or matched
control IgG for 30 minutes and unbound mAb/IgG
washed out. This procedure may enable FcgR-mediated
phagocytosis of myelin that is opsonized by mAb/IgG (Fig-
ure 1E). We blocked, therefore, Fc-segments of anti-CD47
and control IgG to exclude phagocytosis by FcgR( F i g u r e
1F). To this end, mouse anti-rat CD47 mAb and matched
control IgG were incubated with Fab2 fragments of goat
anti-mouse IgG that lack their own Fc-segments. To verify
coating/blocking efficiency, myelin was opsonized by
either Fc-coated or uncoated anti CD47. Bound anti-CD47
was visualized by immunofluorescence confocal micro-
scopy using Cy3-labelled anti-mouse Ab/IgG, which can
bind Fc-uncoated mouse anti-rat CD47 (Figure 1E) but
not Fc-coated mouse anti-rat CD47 (Figure 1D &1F).
Myelin opsonized by Fc-uncoated anti-CD47 displayed
positive immunoreactivity (Figure 2J) whereas myelin
opsonized by Fc-coated anti CD47 did not (Figure 2K).
Thus anti-Fc-Fab2 coated/blocked most, if not all, Fc-
segments of anti CD47.
Myelin opsonized by Fc-coated anti-CD47 or Fc-
coated matched control IgG was added to macrophages
and microglia and phagocytosis assayed. Phagocytosis of
myelin opsonized by Fc-coated anti CD47 was augmen-
ted in both macrophages and microglia 260% and 160%
of control, respectively (Figure 3). Thus, levels of aug-
mentation in the presence of anti-CD47 and anti-SIRPa
were similar.
Myelin CD47 and serum can each promote SIRPa-
dependent down-regulation of myelin phagocytosis in
microglia
SIRPa-dependent down-regulation of CD47
+/+ myelin
phagocytosis suggests augmentation of phagocytosis after
reducing SIRPa levels in phagocytes (Figure 1G &1H).
We knocked-down SIRPa levels (SIRPa-KD) in wild-type
primary Balb/C microglia by Lentiviral infection with
SIRPa-shRNA, down to 3% of levels in control microglia
that were infected with non-target Luciferase-shRNA
(Con-Luc; Figure 4A &4B). Concurrently, phagocytosis of
CD47
+/+ myelin was augmented in SIRPa-KD microglia
330% of control (Figure 4C). It is further expected that
this augmentation will not take place if myelin does not
express CD47 (Figure 1I &1J). However, contrary to pre-
diction, phagocytosis of CD47
-/- myelin was augmented
in SIRPa-KD microglia 220% of control (Figure 4D), sug-
gesting augmentation that is dependent on SIRPa but
independent of myelin CD47. Since experiments were
carried out thus far in medium supplemented by serum,
it is possible that components in serum may have acti-
vated SIRPa directly or indirectly through transactivation
[ 3 0 ] .T oe x c l u d es e r u md e p endent activation of SIRPa,
experiments were repeated in serum-free medium sup-
plemented by 0.1% delipidated BSA. Phagocytosis of
CD47
+/+ myelin was augmented in SIRPa-KD microglia
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myelin can promote SIRPa-dependent down-regulation
of myelin phagocytosis irrespective of serum. Further,
phagocytosis of CD47
-/- myelin in the absence of serum
was not altered from control (Figure 4F), indicating that
augmentation of phagocytosis of CD47
-/- myelin in the
presence of serum (Figure 4D) was serum-dependent.
Thus serum can promote SIRPa-dependent down-
regulation of myelin phagocytosis irrespective of CD47
on myelin.
Discussion
This study provides evidence that myelin regulates its own
phagocytosis by simultaneous activation and down-
regulation in macrophages and microglia (Figure 1A &1B).
Activation follows myelin binding/activating receptors
that mediate its phagocytosis (e.g. CR3 and SRA;
[11-15]). Down-regulation follows myelin CD47 binding
to and activation of SIRPa on macrophages and micro-
glia, which we document here for the first time. Further,
myelin CD47 and serum can each promote SIRPa-
dependent down-regulation of myelin phagocytosis irre-
spective of the other.
Down-regulation of myelin phagocytosis that depends on
myelin CD47 binding to and activation of SIRPa on phago-
cytes is suggested by the following observations: CD47 is
expressed normally on myelin and SIRPa is expressed nor-
mally on microglia and macrophages (Figure 2), which is a
pre-requisite for SIRPa activation in phagocytes by myelin
CD47; phagocytosis of CD47
+/+ myelin is augmented after
blocking binding between CD47 and SIRPa (Figure 3),
indicating that down-regulation of phagocytosis indeed fol-
lows CD47-SIRPa binding; phagocytosis of CD47
+/+ myelin
is augmented after reducing SIRPa levels in phagocytes
(Figure 4C &4E), suggesting that down-regulation of pha-
gocytosis depends on SIRPa in phagocytes; and, finally,
phagocytosis in serum-free medium of CD47
-/- myelin is
not altered from normal in phagocytes with reduced SIRPa
levels (Figure 4F), suggesting that myelin CD47 produces
SIRPa dependent down-regulation of CD47
+/+ myelin pha-
gocytosis irrespective of serum (Figure 4E &4F).
Further, serum can promote SIRPa-dependent down-
regulation of myelin phagocytosis irrespective of myelin
CD47, although both serum and CD47 can produce this
down-regulation at the same time. This is suggested by
the following observations: phagocytosis of CD47
-/- myelin
by phagocytes with reduced SIRPa levels is augmented in
the presence of serum but not in its absence (Figure 4D &
4F), indicating that removal of serum alleviates SIRPa-
dependent down-regulation of phagocytosis in the absence
of myelin CD47; further, augmentation of phagocytosis of
CD47
+/+ myelin by phagocytes with reduced SIRPa levels
in the presence of serum exceeds phagocytosis augmenta-
tion in the absence of serum (Figure 4C &4E), suggesting
that reducing SIRPa levels alleviate both CD47- and
serum-induced, SIRPa-dependent down-regulation of
Figure 3 Myelin phagocytosis is augmented in the presence of anti-CD47and anti-SIRPa function-blocking mAbs (see also Fig. 1).
Myelin phagocytosis is augmented in (A) microglia and (B) macrophages in the presence of function-blocking anti-SIRPa and anti-CD47 mAbs.
Phagocytosis was assayed using different paradigms for each mAb (see text). (i) Microglia and macrophages were pre-incubated in the presence
of anti-SIRPa or matched control IgG (Cont-IgG), myelin was added and phagocytosis was assayed. Phagocytosis in the presence of anti-SIRPa
was calculated as a percentage of the phagocytosis in control IgG, which was defined as 100%. (ii) Anti-CD47 or matched control IgGs that had
their Fc-segments coated/blocked by anti-Fc Fab2 fragments (Fab2-anti-CD47 and Cont-Fab2-IgG, respectively) were used to opsonize myelin
that was added to phagocytes. Phagocytosis of myelin opsonized by Fab2-anti-CD47 was calculated as a percentage of phagocytosis in the
presence of Cont-Fab2-IgG, which was defined as 100%. Values of individual experiments, each performed in triplicates, as well as averages ± SE
are given; two tailed p-values of significance are *** p < 0.001.
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serum promotes SIRPa-dependent down-regulation of
myelin phagocytosis. Potential mechanisms could be
transactivation of SIRPa by other receptor(s) or by as yet
unidentified soluble SIRPa ligand(s) in serum. For exam-
ple, SIRPa may be transactivated by EGFR whose soluble
ligands are present in serum, as has been reported in other
systems [30]. Further studies are required to elucidate
those mechanisms that underlie serum/SIRPa-dependent
down-regulation of phagocytosis.
CD47/SIRPa-dependent inhibition of FcgR- and CR3-
mediated phagocytosis of IgG- and C3bi-opsonized
Figure 4 CD47 on myelin and serum can each promote SIRPa-dependent down-regulation of myelin phagocytosis in microglia with
reduced SIRPa levels. (A) Quantitation of SIRPa levels in Balb/C microglia infected with SIRPa-shRNA (SIRPa-KD) or non-target control
Luciferase-shRNA (Con-Luc) based on (B) immunoblot analyses in which SIRPa and GAPDH levels were determined. An SIRPa to GAPDH ratio in
SIRPa-KD microglia was calculated as a percentage of that ratio in Con-Luc microglia, which was defined as 100%. Values of individual
experiments, averages ± SE and levels of significance are given; two tailed p-value of significance is *** p < 0.001. Phagocytosis of CD47
+/+
myelin is augmented in SIRPa-KD microglia compared to phagocytosis by Con-Luc microglia in both (C) the presence and (E) the absence of
serum. Phagocytosis of CD47
-/- myelin is augmented in SIRPa-KD microglia compared to phagocytosis by Con-Luc microglia in (D) the presence
but not (F) the absence of serum. Phagocytosis by SIRPa-KD microglia was calculated as a percentage of phagocytosis by Con-Luc microglia,
which was defined as 100% (see Methods). Values of individual experiments, each performed in triplicates, averages ± SE and levels of
significance are given; two tailed p-value of significance are ** p < 0.01 and *** p < 0.001.
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Page 8 of 10RBCs and platelets has been previously documented in
macrophages [21-24]. These observations have led to
the notion that CD47 functions as a marker of “self,”
whose physiological role is to protect intact CD47
+/+
RBCs and platelets from activated autologous macro-
phages that express SIRPa. Our present observations
suggest that CD47 may function also as marker of “self”
on myelin and myelin-forming Schwann cells and oligo-
dendrocytes, as CD47 may help protect these cells from
activated macrophages and microglia. This mechanism
could be helpful under normal conditions and in infec-
tious diseases where phagocytes need to be activated to
phagocytose pathogens but bystander intact “self” cell
populations should be spared.
However, this very same mechanism may turn disad-
vantageous after traumatic injury to PNS and CNS
axons and in multiple sclerosis. Rapid phagocytosis of
degenerated myelin, which CD47-SIRPa interaction
impedes, is useful for repair after traumatic injury to
PNS axons, especially in humans; see Background and
[9,10]. The same argument holds for repair after CNS
axonal injury in conjunction with attempts to override
myelin-dependent inhibition of regeneration [31-34]. In
multiple sclerosis, degenerated myelin activates the com-
plement system to form membrane attack complexes,
which then produce damage to intact axons and myelin
and further inhibit remyelination [35-38]. Rapid removal
of degenerated myelin, which CD47-SIRPa interaction
impedes, may harness these detrimental effects.
Conclusions
Myelin phagocytosis is regulated by activation and inhi-
bitory mechanisms, suggesting that the balance between
these two determines how rapid and efficient phagocyto-
sis will be. Inhibitory mechanisms, such as the CD47-
SIRPa interaction that we document here, are useful
under normal conditions and while combating invading
pathogens to protect intact myelin and myelin-forming
oligodendrocytes and Schwann cells from activated
microglia and macrophages. The very same mechanisms
may turn harmful when faster removal of degenerating
myelin is useful (e.g. after traumatic injury and in multi-
ple sclerosis). Further, SIRPa-dependent down-regulation
of phagocytosis may also be promoted by serum.
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